Beovu is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with neovascular AMD.

If you have a Hayes login, click here to view the full report on the Knowledge Center.